#targeted therapy

What Is Targeted Therapy?

Compared with men, women had a 34% greater likelihood of adverse events, especially if they received immunotherapy.

Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.

Pediatric patients were matched to therapies targeting specific mutations found in their cancers.

A new type of cancer treatment uses antibodies to deliver chemotherapy drugs directly to tumors.

A look back at some of the most important science and treatment news Cancer Health covered this year.

Immunotherapy was far more effective than targeted therapy in extending survival for people with certain kinds of advanced melanoma.

A new generation of precision cancer therapies are easier to tolerate than traditional treatment.

Next-generation genomic testing improved the effectiveness of targeted therapies for certain patients with metastatic breast cancer.

Study is first to show benefit of any targeted drugs in glioblastomas—the most aggressive brain tumors.

Scemblix was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.

People who received the antibody-drug conjugate were also more likely to experience tumor remission.

Data from early clinical trials suggest new precision cancer treatments are on the horizon.

The targeted therapy delayed disease progression or death by approximately nine months.

Adding the CDK 4/6 inhibitor to hormone prolonged survival by a year.

Exkivity is approved for adults with advanced non-small-cell lung cancer with specific EGFR mutations.